702 related articles for article (PubMed ID: 25770404)
21. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
[No Abstract] [Full Text] [Related]
22. Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort.
Saini S; Folta AN; Harsh KL; Stanek JR; Dunn AL; O'Brien SH; Kumar R
J Pediatr; 2019 Jun; 209():212-219.e1. PubMed ID: 30961988
[TBL] [Abstract][Full Text] [Related]
23. Developing an Anti-Xa-Based Anticoagulation Protocol for Patients with Percutaneous Ventricular Assist Devices.
Sieg A; Mardis BA; Mardis CR; Huber MR; New JP; Meadows HB; Cook JL; Toole JM; Uber WE
ASAIO J; 2015; 61(5):502-8. PubMed ID: 26273933
[TBL] [Abstract][Full Text] [Related]
24. Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery.
Oladunjoye OO; Sleeper LA; Nair AG; Trenor CC; VanderPluym C; Kheir JN; Emani SM
J Thorac Cardiovasc Surg; 2018 Jul; 156(1):332-340.e1. PubMed ID: 29709361
[TBL] [Abstract][Full Text] [Related]
25. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
[TBL] [Abstract][Full Text] [Related]
26. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
[TBL] [Abstract][Full Text] [Related]
27. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization.
Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548
[TBL] [Abstract][Full Text] [Related]
28. Discordance between aPTT and anti-Xa in monitoring heparin anticoagulation in mechanical circulatory support.
Li S; Li A; Beckman JA; Kim C; Granich MA; Mondin J; Sabath DE; Garcia DA; Mahr C
ESC Heart Fail; 2024 May; ():. PubMed ID: 38725133
[TBL] [Abstract][Full Text] [Related]
29. The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay.
Kostousov V; Nguyen K; Hundalani SG; Teruya J
Arch Pathol Lab Med; 2014 Nov; 138(11):1503-6. PubMed ID: 25357112
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time.
Coons JC; Iasella CJ; Thornberg M; Fitzmaurice MG; Goehring K; Jablonski L; Leader D; Meyer A; Seo H; Benedict NJ; Smith RE
Am J Hematol; 2019 Sep; 94(9):1015-1019. PubMed ID: 31243789
[TBL] [Abstract][Full Text] [Related]
31. Concordance between Activated Partial Thromboplastin Time and Antifactor Xa Assay for Monitoring Unfractionated Heparin in Hospitalized Hyperbilirubinemic Patients.
Mahmoud L; Zullo AR; McKaig D; Berard-Collins CM
R I Med J (2013); 2016 Mar; 99(3):33-7. PubMed ID: 26929970
[TBL] [Abstract][Full Text] [Related]
32. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin.
van Roessel S; Middeldorp S; Cheung YW; Zwinderman AH; de Pont AC
Neth J Med; 2014 Jul; 72(6):305-10. PubMed ID: 25319855
[TBL] [Abstract][Full Text] [Related]
33. Anticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time?
Monteagudo-Vela M; Bowles C; Raj B; Robinson D; Simon A
Interact Cardiovasc Thorac Surg; 2022 Jan; 34(2):322-325. PubMed ID: 34849924
[TBL] [Abstract][Full Text] [Related]
34. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS
Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of unfractionated heparin in critically ill patients.
Aarab R; van Es J; de Pont AC; Vroom MB; Middeldorp S
Neth J Med; 2013 Nov; 71(9):466-71. PubMed ID: 24218420
[TBL] [Abstract][Full Text] [Related]
36. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time.
Cuker A; Ptashkin B; Konkle BA; Pipe SW; Whinna HC; Zheng XL; Cines DB; Pollak ES
J Thromb Haemost; 2009 Jan; 7(1):80-6. PubMed ID: 19017257
[TBL] [Abstract][Full Text] [Related]
37. Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation.
Sandner SE; Riebandt J; Haberl T; Mahr S; Rajek A; Schima H; Wieselthaler GM; Laufer G; Zimpfer D
J Heart Lung Transplant; 2014 Jan; 33(1):88-93. PubMed ID: 24239003
[TBL] [Abstract][Full Text] [Related]
38. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study.
Bauer SR; Ou NN; Dreesman BJ; Armon JJ; Anderson JA; Cha SS; Oyen LJ
Mayo Clin Proc; 2009 Dec; 84(12):1073-8. PubMed ID: 19955244
[TBL] [Abstract][Full Text] [Related]
39. Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms.
Whitman-Purves E; Coons JC; Miller T; DiNella JV; Althouse A; Schmidhofer M; Smith RE
Clin Appl Thromb Hemost; 2018 Mar; 24(2):310-316. PubMed ID: 29212374
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
Dingus SJ; Smith AR; Dager WE; Zochert S; Nothdurft SA; Gulseth MP
Ann Pharmacother; 2022 Dec; 56(12):1289-1298. PubMed ID: 35499336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
